['acute ischaemic stroke', 'transient ischaemic attack']
['ticagrelor', 'acetylsalicylic acid (asa)']

        Inclusion Criteria:

          -  Men or women equal or elder 40 years of age

          -  Either acute ischaemic stroke or high-risk TIA as defined here and randomisation
             occurring within 24 hours after onset of symptoms

        Key Exclusion Criteria:

          -  Planned use of antithrombotic therapy in addition to study medication including
             antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine,
             prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral
             thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated
             and low molecular weight heparins). - Any history of atrial fibrillation, ventricular
             aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid,
             cerebrovascular, or coronary revascularisation that requires halting study medication
             within 7 days of randomisation. - Receipt of any intravenous or intra-arterial
             thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation -
             History of previous symptomatic non-traumatic intracerebral bleed at any time
             (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past
             6 months, or major surgery within 30 days.
      